The UK has leveraged its independence post-Brexit to foster a pro-innovation environment for advanced therapy medicinal products (ATMPs), combining streamlined approval processes with robust support through the Medicines and Healthcare Products Regulatory Agency (MHRA), Health Technology Assessment (HTA) bodies and the NHS, as well as through the Innovative Licensing and Access Pathway (ILAP) and the Cell and Gene Therapy Catapult (CGT Catapult). Alongside investments in regulatory science, clinical trial enhancements, transparent and flexible market access processes, the UK fosters rapid adoption of cutting-edge therapies.
In this whitepaper, CGT Catapult's experts provide a comprehensive overview of the UK's regulatory and market access landscape for ATMP development and adoption, highlighting the areas of favourable differentiation from other geographies.
View the whitepaper summary infographic
